KURA ONCOLOGY, INC. Costs and Expenses
KURA ONCOLOGY, INC. (KURA) reported Costs and Expenses of $93.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-12
- KURA ONCOLOGY, INC. costs and expenses for the quarter ending 2026-06-30 was $93.88M, a 6.74% increase year-over-year.
- KURA ONCOLOGY, INC. costs and expenses for the quarter ending 2026-03-31 was $97.08M, a 23.19% increase year-over-year.
- KURA ONCOLOGY, INC. costs and expenses for the quarter ending 2025-06-30 was $87.95M.
- KURA ONCOLOGY, INC. costs and expenses for the quarter ending 2025-03-31 was $78.81M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month |
|---|---|---|
| 2026-06-30 | $93.88M 10-Q · filed 2026-08-12 | $190.96M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $97.08M 10-Q · filed 2026-05-12 | |
| 2025-06-30 | $87.95M 10-Q · filed 2026-08-12 | $166.76M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $78.81M 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |